abYsis: Integrated Antibody Sequence and Structure—Management, Analysis, and Prediction

Journal of Molecular Biology

Volumn 429, Issue 3, 2017, Pages 356-364

  Swindells, Mark B ^a   Porter, Craig T ^b   Couch, Matthew ^b   Hurst, Jacob ^b,c   Abhinandan, K R ^b,d   Nielsen, Jens H ^b   Macindoe, Gary ^b   Hetherington, James ^b   Martin, Andrew C R ^b  

^a Chemogenomix   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Immunocore Limited   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

antibodies; antibody humanization; bioinformatics and computational biology; databases; sequence analysis

Indexed keywords

ANTIBODY; COMPLEMENTARITY DETERMINING REGION;

ANTIBODY AND IMMUNOGLOBULIN STRUCTURE; ANTIBODY SEQUENCE; ANTIBODY STRUCTURE; ARTICLE; COMPLEMENTARITY DETERMINING REGION; DATA BASE; DOMESTIC HORSE; DROMEDARY; GINGLYMOSTOMA CIRRATUM; HEAVY CHAIN; HUMAN; LIGHT CHAIN; LLAMA; MUS MUSCULUS; NONHUMAN; ONCORHYNCHUS MYKISS; ORYCTOLAGUS CUNICULUS; PREDICTION; PRIORITY JOURNAL; PROTEIN DATA BANK; PROTEIN PROCESSING; RHESUS MONKEY; SEQUENCE ALIGNMENT; AMINO ACID SEQUENCE; ANIMAL; BIOLOGY; CHEMISTRY; INTERNET; PROTEIN DATABASE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; COMPLEMENTARITY DETERMINING REGIONS; COMPUTATIONAL BIOLOGY; DATABASES, PROTEIN; HUMANS; INTERNET; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84994140652     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2016.08.019     Document Type: Article

References (60)

1. [1] Glanville, J., Zhai, W., Berka, J., Telman, D., Huerta, G., Mehta, G.R., Ni, I., Mei, L., Sundar, P.D., Day, G.M.R., Cox, D., Rajpal, A., Pons, J., Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 20,216–20,221.
2. [2] Yamada, T., Therapeutic monoclonal antibodies. Keio J. Med. 60 (2011), 37–46.
3. [3] Bagshawe, K.D., Targeting: the ADEPT story so far. Curr. Drug Targets 10 (2009), 152–157.
4. [4] Reusch, U., Harrington, K., Gudgeon, C., Fucek, I., Ellwanger, K., Weichel, M., Knackmuss, S., Zhukovsky, E., Fox, J.A., Kunkel, L.A., Guenot, J., Walter, R.B., Characterization of CD33/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia. Clin. Cancer Res., 2016, 10.1158/1078-0432.CCR-16-0350 (Epub ahead of print]).
5. [5] Chen, X., Haddish-Berhane, N., Moore, P., Clark, T., Yang, Y., Li, H., Xuan, D., Barton, H., Betts, A., Barletta, F., Mechanistic projection of first in human dose for bispecific immuno-modulatory P-cadherin LP-DART—an integrated PK/PD modeling approach. Clin. Pharmacol. Ther. 100 (2016), 232–241.
6. [6] Torres, T., Romanelli, M., Chiricozzi, A., A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin. Investig. Drugs 25 (2016), 751–754.
7. [7] Abhinandan, K.R., Martin, A.C.R., Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains. Mol. Immunol. 45 (2008), 3832–3839.
8. [8] Reichert, J.M., Valge-Archer, V.E., Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 6 (2007), 349–356.
9. [9] Ecker, D.M., Jones, S.D., Levine, H.L., The therapeutic monoclonal antibody market. MAbs 7 (2015), 9–14.
10. [10] Larson, R.A., Boogaerts, M., Estey, E., Karanes, C., Stadtmauer, E.A., Sievers, E.L., Mineur, P., Bennett, J.M., Berger, M.S., Eten, C.B., Munteanu, M., Loken, M.R., van Dongen, J.J.M., Bernstein, I.D., Appelbaum, F.R., Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 16 (2002), 1627–1636.
11. [11] Berard, J.L., Velez, R.L., Freeman, R.B., Tsunoda, S.M., A review of interleukin-2 receptor antagonists in solid organ transplantation. Pharmacotherapy 19 (1999), 1127–1137.
12. [12] Maini, R., Clair, E.W.S., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., Lipsky, P., Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354 (1999), 1932–1939.
13. [13] Sáez-Llorens, X., Castaño, E., Null, D., Steichen, J., Sánchez, P.J., Ramilo, O., Top, F.H., Connor, E., Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J. 17 (1998), 787–791.
14. [14] Sandborn, W.J., Hanauer, S.B., Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm. Bowel Dis. 5 (1999), 119–133.
15. [15] Wang, W., Singh, S., Zeng, D.L., King, K., Nema, S., Antibody structure, instability, and formulation. J. Pharm. Sci. 96 (2007), 1–26.
16. [16] Mackay, I.R., Rosen, F.S., Delves, P.J., Roitt, I.M., The immune system. N. Engl. J. Med. 343 (2000), 37–49.
17. [17] Brekke, O.H., Sandlie, I., Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2 (2003), 52–62.
18. [18] Weiner, G.J., Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer 15 (2015), 361–370.
19. [19] Schroff, R.W., Foon, K.A., Beatty, S.M., Oldham, R.K., Morgan, A.C., Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 45 (1985), 879–885.
20. [20] Shawler, D.L., Bartholomew, R.M., Smith, L.M., Dillman, R.O., Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 135 (1985), 1530–1535.
21. [21] Hwang, W.Y.K., Foote, J., Immunogenicity of engineered antibodies. Methods 36 (2005), 3–10.
22. [22] Kohler, G., Milstein, C., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (London) 256 (1975), 495–497.
23. [23] Green, L.L., Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods 231 (1999), 11–23.
24. [24] Winter, G., Milstein, C., Man-made antibodies. Nature (London), 349, 1991, 293.
25. [25] Tickle, S., Adams, R., Brown, D., Griffiths, M., Lightwood, D., Lawson, A., High-throughput screening for high affinity antibodies. J. Lab. Autom. 14 (2009), 303–307.
26. [26] McCafferty, J., Griffiths, A.D., Winter, G., Chiswell, D.J., Phage antibodies—filamentous phage displaying antibody variable domains. Nature (London) 348 (1990), 552–554.
27. [27] Nixon, A.E., Sexton, D.J., Ladner, R.C., Drugs derived from phage display: from candidate identification to clinical practice. MAbs 6 (2014), 73–85.
28. [28] Jones, P.T., Dear, P.H., Foote, J., Neuberger, M.S., Winter, G., Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (London) 321 (1986), 522–525.
29. [29] Verhoeyen, M., Milstein, C., Winter, G., Reshaping human antibodies: grafting an antilysozyme activity. Science 239 (1988), 1534–1536.
30. [30] Riechmann, L., Clark, M., Waldmann, H., Winter, G., Reshaping human antibodies for therapy. Nature 332 (1988), 323–327.
31. [31] Lefranc, M.-P., Giudicelli, V., Duroux, P., Jabado-Michaloud, J., Folch, G., Aouinti, S., Carillon, E., Duvergey, H., Houles, A., Paysan-Lafosse, T., Hadi-Saljoqi, S., Sasorith, S., Lefranc, G., Kossida, S., IMGT, the international ImMunoGeneTics information system 25 years on. Nucleic Acids Res. 43 (2015), D413–D422.
32. [32] Almagro, J.C., Teplyakov, A., Luo, J., Sweet, R.W., Kodangattil, S., Hernandez-Guzman, F., Gilliland, G.L., Second antibody modeling assessment (AMA-II). Proteins Struct. Funct. Genet. 82 (2014), 1553–1562.
33. [33] Marcatili, P., Rosi, A., Tramontano, A., PIGS: automatic prediction of antibody structures. Bioinformatics 24 (2008), 1953–1954.
34. [34] Dunbar, J., Krawczyk, K., Leem, J., Marks, C., Nowak, J., Regep, C., Georges, G., Kelm, S., Popovic, B., Deane, C.M., SAbPred: a structure-based antibody prediction server. Nucleic Acids Res. 44:W1 (2016), W474–W478.
35. [35] Sircar, A., Kim, E.T., Gray, J.J., RosettaAntibody: antibody variable region homology modeling server. Nucleic Acids Res. 37 (2009), W474–W479.
36. [36] Weitzner, B.D., Kuroda, D., Marze, N., Xu, J., Gray, J.J., Blind prediction performance of RosettaAntibody 3.0: grafting, relaxation, kinematic loop modeling, and full CDR optimization. Proteins 82 (2014), 1611–1623.
37. [37] Shirai, H., Ikeda, K., Yamashita, K., Tsuchiya, Y., Sarmiento, J., Liang, S., Morokata, T., Mizuguchi, K., Higo, J., Standley, D.M., Nakamura, H., High-resolution modeling of antibody structures by a combination of bioinformatics, expert knowledge, and molecular simulations. Proteins 82 (2014), 1624–1635.
38. [38] Berrondo, M., Kaufmann, S., Berrondo, M., Automated Aufbau of antibody structures from given sequences using Macromoltek's SmrtMolAntibody. Proteins 82 (2014), 1636–1645.
39. [39] Dunbar, J., Deane, C.M., ANARCI: antigen receptor numbering and receptor classification. Bioinformatics 32 (2016), 298–300.
40. [40] Dunbar, J., Krawczyk, K., Leem, J., Baker, T., Fuchs, A., Georges, G., Shi, J., Deane, C.M., SAbDab: the structural antibody database. Nucleic Acids Res. 42 (2014), D1140–D1146.
41. [41] Olimpieri, P.P., Marcatili, P., Tramontano, A., Tabhu: tools for antibody humanization. Bioinformatics 31 (2015), 434–435.
42. [42] Chailyan, A., Tramontano, A., Marcatili, P., A database of immunoglobulins with integrated tools: DIGIT. Nucleic Acids Res. 40 (2012), D1230–D1234.
43. [43] Martin, A.C., Accessing the Kabat antibody sequence database by computer. Proteins 25 (1996), 130–133.
44. [44] Allcorn, L.C., Martin, A.C.R., SACS—self-maintaining database of antibody crystal structure information. Bioinformatics 18 (2002), 175–181.
45. [45] Abhinandan, K.R., Martin, A.C.R., Analyzing the “degree of humanness” of antibody sequences. J. Mol. Biol. 369 (2007), 852–862.
46. [46] Thullier, P., Huish, O., Pelat, T., Martin, A.C.R., The humanness of macaque antibody sequences. J. Mol. Biol. 396 (2010), 1439–1450.
47. [47] Abhinandan, K.R., Martin, A.C.R., Analysis and prediction of VH/VL packing in antibodies. Protein Eng. Des. Sel. 23 (2010), 689–697.
48. [48] Martin, A.C., Thornton, J.M., Structural families in loops of homologous proteins: automatic classification, modelling and application to antibodies. J. Mol. Biol. 263 (1996), 800–815.
49. [49] Johnson, G., Wu, T.T., Kabat database and its applications: future directions. Nucleic Acids Res. 29 (2001), 205–206.
50. [50] Berman, H.M., Battistuz, T., Bhat, T.N., Bluhm, W.F., Bourne, P.E., Burkhardt, K., Feng, Z., Gilliland, G.L., Iype, L., Jain, S., Fagan, P., Marvin, J., Padilla, D., Ravichandran, V., Schneider, B., Thanki, N., Weissig, H., Westbrook, J.D., Zardecki, C., The Protein Data Bank. Acta Crystallogr. D Biol. Crystallogr. 58 (2002), 899–907.
51. [51] Martin, A.C.R., Viewing multiple sequence alignments with the JavaScript sequence alignment viewer (JSAV). F1000Res., 3, 2014, 249.
52. [52] Al-Lazikani, B., Lesk, A.M., Chothia, C., Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 273 (1997), 927–948.
53. [53] Adair, J.R., Engineering antibodies for therapy. Immunol. Rev. 130 (1992), 5–40.
54. [54] Smith-Gill, S.J., Mainhart, C.R., Lavoie, T.B., Rudikoff, S., Potter, M., VL-VH expression by monoclonal antibodies recognizing avian lysozyme. J. Immunol. 132 (1984), 963–967.
55. [55] MacCallum, R.M., Martin, A.C., Thornton, J.M., Antibody–antigen interactions: contact analysis and binding site topography. J. Mol. Biol. 262 (1996), 732–745.
56. [56] Wu, T.T., Johnson, G., Kabat, E.A., Length distribution of CDRH3 in antibodies. Proteins 16 (1993), 1–7.
57. [57] Johnson, G., Wu, T.T., Preferred CDRH3 lengths for antibodies with defined specificities. Int. Immunol. 10 (1998), 1801–1805.
58. [58] Collis, A.V.J., Brouwer, A.P., Martin, A.C.R., Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J. Mol. Biol. 325 (2003), 337–354.
59. [59] Barrios, Y., Jirholt, P., Ohlin, M., Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor. J. Mol. Recognit. 17 (2004), 332–338.
60. [60] Hanson, R.M., Prilusky, J., Zhou, R., Nakane, T., Sussman, J.L., JSmol and the next-generation web-based representation of 3D molecular structure as applied to Proteopedia. Isr. J. Chem. 53 (2013), 207–216.